STA551

STA551 is a humanized monoclonal antibody engineered to selectively activate **CD137** (also known as **4-1BB**, a member of the tumor necrosis factor receptor superfamily) only in the presence of elevated extracellular adenosine triphosphate (ATP), a distinguishing feature of the tumor microenvironment in solid tumors. This "switch" mechanism translates into tumor-selective immune activation and avoids systemic immune activation, aiming to minimize off-tumor toxicity. STA551 has demonstrated potent and broad antitumor efficacy in both murine and human tumor models, maintaining a wide therapeutic window and tolerability at high doses in preclinical studies. It is currently in phase I clinical trials as both monotherapy and in combination with atezolizumab for solid tumors. STA551 is developed using Chugai's proprietary Switch-Ig technology[1][2][3][6][8][9].

Other names

Anti-CD137 agonistic Switch antibodyAnti-CD-137 agonistic Switch antibodyAnti-CD 137 agonistic Switch antibodyCD137 agonist switch antibodyCD-137 agonist switch antibodyCD 137 agonist switch antibody